Manfred Ruediger
Member of the board
Management
Medigene
Sweden
Biography
Dr. Manfred Ruediger was Chief Executive Officer (CEO) of Kiadis Pharma until April 2017. He joined Kiadis Pharma in 2011 and has led the development of the company towards a company with late-stage clinical development and pre-commercialization stages. Kiadis Pharma is listed on Euronext in Amsterdam and Brussels since 2015. Prior to joining Kiadis Pharma, he was Chief Scientific Officer and acting CEO of Cardion AG, CEO of Igeneon AG, Chief Operating Officer of NASDAQ-listed Aphton Corporation, and lastly CEO of t2cure GmbH and Affectis AG. Since August 2005, he is member of the Supervisory Board of 4SC AG. Dr. Ruediger holds a PhD in Biochemistry from the Max-Planck-Institute for Biophysical Chemistry in Göttingen, Germany, and worked at the Technical University of Braunschweig, Germany, before he joined the industry.
Research Interest
Late-stage clinical development
